共 98 条
[1]
Fruchart JC(2008)The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 1K-34K
[2]
Sacks F(1977)High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study Am J Med 62 707-714
[3]
Hermans MP(2011)HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms Nat Rev Cardiol 8 222-232
[4]
Gordon T(2011)Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis Curr Atheroscler Rep 13 107-114
[5]
Castelli WP(2000)A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits Nature 406 203-207
[6]
Hjortland MC(2010)Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport J Lipid Res 51 3443-3454
[7]
Navab M(2009)Safety and tolerability of dalcetrapib Am J Cardiol 104 82-91
[8]
Reddym ST(2010)Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial Eur Heart J 31 480-488
[9]
Van Lenten BJ(2012)Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study Am Heart J 163 515-521
[10]
Farmer JA(2009)Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome Am Heart J 158 896-901